Overall, this study underscores the effectiveness of multi-omics approaches in revealing the molecular mechanisms driving chemotherapy responses in cancer cells. Additionally, this work generates a comprehensive list of molecular alterations that can serve as a foundation for further investigations and inform personalized healthcare strategies to enhance patient outcomes.

2 days ago

Journal

HIF1A (Hypoxia inducible factor 1, alpha subunit) • RACK1 (Receptor For Activated C Kinase 1) • RPA3 (Replication Protein A3)

paclitaxel • topotecan

PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer (ChiCTR2400091077)

P3, N=404, Recruiting, Jilin Cancer Hospital; Jilin Cancer Hospital

8 days ago

New P3 trial • Combination therapy

paclitaxel • topotecan • BNT327

JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer (ChiCTR2400090371)

P3, N=394, Not yet recruiting, Jilin Cancer Hospital; Jilin Cancer Hospital

8 days ago

New P3 trial

topotecan • pegylated irinotecan (SSS22)

11d

Retinoblastoma Phase II Expanded Access Clinical Trial (clinicaltrials.gov)

P2, N=30, Not yet recruiting, Targeted Therapy Technologies, LLC

11 days ago

New P2 trial

topotecan • topotecan episcleral

17d

Rapid Administration Pilot for Infusing Dinutuximab (clinicaltrials.gov)

P4, N=11, Suspended, Children's Hospital Los Angeles | Trial completion date: Aug 2024 --> Jun 2025 | Recruiting --> Suspended | Trial primary completion date: Aug 2024 --> Jun 2025

17 days ago

Trial completion date • Trial suspension • Trial primary completion date

temozolomide • cyclophosphamide • irinotecan • topotecan • Unituxin (dinutuximab)

17d

Mobocertinib antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells: in vitro and in vivo studies. (PubMed, Cancer Lett)

In the tumor-bearing mouse model, mobocertinib boosted the antitumor effect of paclitaxel and topotecan, resulting in tumor regression. In summary, our study uncovers a novel potential for repurposing mobocertinib as a dual inhibitor of ABCB1 and ABCG2, and suggests the combination of mobocertinib with substrate drugs as a strategy to counteract MDR.

17 days ago

Preclinical • Journal

ABCB1 (ATP Binding Cassette Subfamily B Member 1) • ABCG2 (ATP Binding Cassette Subfamily G Member 2)

EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation • ABCB1 overexpression • ABCG2 expression

paclitaxel • topotecan • Exkivity (mobocertinib)

26d

REJOICE-Ovarian01: A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov)

P2/3, N=650, Active, not recruiting, Daiichi Sankyo | Recruiting --> Active, not recruiting

26 days ago

Enrollment closed

gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan • raludotatug deruxtecan (DS-6000)

28d

MEF2C is a Potential Prognostic Biomarker and is Correlated with Immune Infiltrates in Lung Adenocarcinoma. (PubMed, Curr Med Chem)

The results imply that MEF2C could be a valuable indicator for predicting outcomes and a possible target for immunotherapy for LUAD patients.

28 days ago

Journal • Tumor mutational burden • IO biomarker

TMB (Tumor Mutational Burden) • MEF2C (Myocyte Enhancer Factor 2C)

Tasigna (nilotinib) • irinotecan • topotecan • Farydak (panobinostat)

Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma (clinicaltrials.gov)

P3, N=110, Not yet recruiting, Children's Oncology Group

1 month ago

New P3 trial • Surgery

TP53 (Tumor protein P53) • DICER1 (Dicer 1 Ribonuclease III)

doxorubicin hydrochloride • cyclophosphamide • ifosfamide • vincristine • daunorubicin • topotecan • dactinomycin • dexrazoxane

NCI-2018-03732: Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma (clinicaltrials.gov)

P2, N=42, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2024 --> Sep 2025

1 month ago

Trial completion date

MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • IL6 (Interleukin 6) • CXCL9 (Chemokine (C-X-C motif) ligand 9)

MYCN amplification • IL6 expression

cisplatin • carboplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • Leukine (sargramostim) • dexrazoxane

ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer (clinicaltrials.gov)

P3, N=460, Recruiting, Hansoh BioMedical R&D Company | Not yet recruiting --> Recruiting

1 month ago

Enrollment open

topotecan • GSK5764227

2ms

Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer (clinicaltrials.gov)

P3, N=530, Not yet recruiting, Genmab

2 months ago

New P3 trial

gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan • rinatabart sesutecan (PRO1184)

2ms

ATR inhibition activates cancer cell cGAS/STING-interferon signaling and promotes antitumor immunity in small-cell lung cancer. (PubMed, Sci Adv)

This study shows that targeting ATR up-regulates major histocompatibility class I expression in preclinical models and SCLC clinical samples collected from a first-in-class clinical trial of ATR inhibitor, berzosertib, with topotecan in patients with relapsed SCLC. Targeting ATR represents a transformative vulnerability of SCLC and is a complementary strategy to induce STING-interferon signaling-mediated immunogenicity in SCLC.

2 months ago

Journal • PD(L)-1 Biomarker • IO biomarker

STING (stimulator of interferon response cGAMP interactor 1)

berzosertib (M6620) • topotecan

2ms

PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer (clinicaltrials.gov)

P3, N=404, Not yet recruiting, Biotheus Inc.

2 months ago

New P3 trial • Combination therapy

paclitaxel • topotecan • BNT327

2ms

A Phase III Study to Evaluate the Efficacy and Safety of YL201 in Relapsed Small Cell Lung Cancer (clinicaltrials.gov)

P3, N=438, Not yet recruiting, MediLink Therapeutics (Suzhou) Co., Ltd.

2 months ago

New P3 trial

topotecan • YL201

2ms

Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer (clinicaltrials.gov)

P1/2, N=88, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Aug 2024 --> Aug 2025

2 months ago

Trial completion date

BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)

veliparib (ABT-888) • topotecan

2ms

DAREONTM-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy (clinicaltrials.gov)

P1, N=54, Recruiting, Boehringer Ingelheim | Trial completion date: Dec 2025 --> Apr 2026

2 months ago

Trial completion date • Combination therapy

PD-L1 (Programmed death ligand 1)

topotecan • obrixtamig (BI 764532)

2ms

NCI-2015-00693: Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy or Immunotherapy Agents in Patients with Advanced Malignancies (clinicaltrials.gov)

P1, N=221, Terminated, M.D. Anderson Cancer Center | Trial completion date: Dec 2024 --> Sep 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2024 --> Sep 2024; Administratively Complete

2 months ago

Trial completion date • Trial termination • Trial primary completion date • Combination therapy • IO biomarker • Metastases

Keytruda (pembrolizumab) • Opdivo (nivolumab) • Lynparza (olaparib) • Yervoy (ipilimumab) • carboplatin • paclitaxel • doxorubicin hydrochloride • capecitabine • cyclophosphamide • pemetrexed • oxaliplatin • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • daunorubicin • topotecan • leucovorin calcium • fluorouracil topical • Pemfexy (pemetrexed)

2ms

A Prospective, Single-Arm, Exploratory Clinical Study of Anti-PD-1 Monoclonal Antibody Combined with Topotecan Capsules for Consolidation of Limited Stage Small Cell Lung Cancer That Has Not Progressed After Concurrent or Sequential Chemoradiotherapy (ChiCTR2400088636)

P=N/A, N=46, Recruiting, Shandong First Medical University Affiliated Cancer Hospital; Shandong First Medical University Affiliated Cancer Hospital

2 months ago

New trial

Loqtorzi (toripalimab-tpzi) • topotecan

2ms

Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors (clinicaltrials.gov)

P2, N=128, Active, not recruiting, Pfizer | Phase classification: P1/2 --> P2 | Trial completion date: Feb 2025 --> Oct 2025

2 months ago

Phase classification • Trial completion date • Combination therapy

EWSR1 (EWS RNA Binding Protein 1) • FUS (FUS RNA Binding Protein)

Ibrance (palbociclib) • temozolomide • cyclophosphamide • irinotecan • topotecan

2ms

A Study of GSK5764227 in Participants With Advanced Solid Tumors (clinicaltrials.gov)

P1, N=260, Not yet recruiting, GlaxoSmithKline | N=100 --> 260

2 months ago

Enrollment change • Metastases

topotecan • GSK5764227

3ms

JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)

P3, N=394, Not yet recruiting, JenKem Technology Co., Ltd.

3 months ago

New P3 trial

topotecan • pegylated irinotecan (SSS22)

3ms

REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 (clinicaltrials.gov)

P2/3, N=600, Recruiting, Sutro Biopharma, Inc. | Trial completion date: Feb 2026 --> Feb 2028 | Trial primary completion date: Sep 2025 --> Aug 2027

3 months ago

Trial completion date • Trial primary completion date

FOLR1 ( Folate receptor alpha )

gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan • luveltamab tazevibulin (STRO-002) • Neulasta (pegfilgrastim)

3ms

A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma (clinicaltrials.gov)

P1, N=71, Active, not recruiting, Eli Lilly and Company | Trial completion date: Aug 2024 --> Aug 2025

3 months ago

Trial completion date

cyclophosphamide • topotecan • LY3295668

3ms

BL-B01D1-304: A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer (clinicaltrials.gov)

P3, N=652, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting

3 months ago

Enrollment open

topotecan • izalontamab brengitecan (BL-B01D1)

3ms

Ubiquitin-specific protease 22 controls melanoma metastasis and vulnerability to ferroptosis through targeting SIRT1/PTEN/PI3K signaling. (PubMed, MedComm (2020))

Finally, we found that both pharmacological and genetic silence of USP22 sensitize RSL3-induced ferroptosis through suppressing the PI3K/Akt/mTOR pathway and its downstream SCD, and ferroptosis inhibitor could partly rescued the decreased lung metastasis by topotecan in vivo. Overall, our findings reveal a prometastatic role of USP22 and identify topotecan as a potent USP22-targeting drug to limit melanoma metastasis.

3 months ago

Journal

PTEN (Phosphatase and tensin homolog) • USP22 (Ubiquitin Specific Peptidase 22)

topotecan • RSL3

3ms

A Study of GSK5764227 in Participants With Advanced Solid Tumors (clinicaltrials.gov)

P1, N=100, Not yet recruiting, GlaxoSmithKline

3 months ago

New P1 trial • Metastases

topotecan • GSK5764227

3ms

Synergistic antitumor effect of liposomal-based formulations of olaparib and topotecan in primary epithelial ovarian cancer cells. (PubMed, Cancer Cell Int)

The concentration-dependent response of different ovarian cancer cell types to combination therapy confirms the need for in vitro optimization to maximize drug cytotoxicity. The OLL and TLL combination is a promising formulation for further animal studies, especially for eliminating epithelial ovarian cancer with wild-type BRCA1/2.

3 months ago

Journal • BRCA Biomarker • PARP Biomarker

BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)

Lynparza (olaparib) • topotecan

3ms

Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors (clinicaltrials.gov)

P1/2, N=231, Recruiting, Novartis Pharmaceuticals | Trial primary completion date: Oct 2028 --> Feb 2029

3 months ago

Trial primary completion date • Combination therapy

MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1)

temozolomide • Kisqali (ribociclib) • topotecan

3ms

Oral Topotecan With Toripalimab for Patients With Endometrial Cancer (clinicaltrials.gov)

P2, N=30, Not yet recruiting, Fudan University

3 months ago

New P2 trial • Combination therapy • Metastases

Loqtorzi (toripalimab-tpzi) • topotecan

3ms

SHR-A1921-303: SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer (clinicaltrials.gov)

P3, N=440, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting --> Recruiting

3 months ago

Enrollment open

paclitaxel • doxorubicin hydrochloride • topotecan • SHR-A1921

3ms

Mechanism and rational combinations with GP-2250, a novel oxathiazine derivative, in ovarian cancer. (PubMed, Cancer Med)

Taken together, our data indicate that GP-2250 exerts profound effects on tumor metabolism and, in combination with PARP inhibitors or bevacizumab, showed promising anti-tumor efficacy. These findings could have implications for the clinical development of GP-2250.

3 months ago

Journal • PARP Biomarker

HIF1A (Hypoxia inducible factor 1, alpha subunit) • HK2 (Hexokinase 2) • ANXA5 (Annexin A5)

Avastin (bevacizumab) • cisplatin • paclitaxel • topotecan • misetionamide (GP-2250)

3ms

NRG-GY023: Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents (clinicaltrials.gov)

P2, N=120, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2025 --> Jun 2025

3 months ago

Trial completion date • Combination therapy

PD-L1 (Programmed death ligand 1) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)

Avastin (bevacizumab) • Lynparza (olaparib) • Imfinzi (durvalumab) • paclitaxel • pegylated liposomal doxorubicin • topotecan • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin)

4ms

DeLLphi-304: Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer (clinicaltrials.gov)

P3, N=509, Active, not recruiting, Amgen | Recruiting --> Active, not recruiting

4 months ago

Enrollment closed

topotecan • Zepzelca (lurbinectedin) • Imdelltra (tarlatamab-dlle) • Calsed (amrubicin)

4ms

MIRASOL: A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression (clinicaltrials.gov)

P3, N=453, Active, not recruiting, ImmunoGen, Inc. | Trial completion date: Apr 2024 --> Aug 2024

4 months ago

Trial completion date • Metastases

FOLR1 ( Folate receptor alpha )

paclitaxel • pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • topotecan

4ms

RN486, a Bruton's Tyrosine Kinase inhibitor, antagonizes multidrug resistance in ABCG2-overexpressing cancer cells. (PubMed, J Transl Int Med)

Non-toxic concentrations of RN486 remarkably increased the sensitivity of ABCG2-overexpressing cancer cells to conventional anticancer drugs mitoxantrone and topotecan. Our studies propose that RN486 can antagonize ABCG2-mediated MDR in cancer cells via down-regulating the expression level of ABCG2 protein, reducing ATPase activity of ABCG2 transporter, and inhibiting the transporting function. RN486 could be potentially used in conjunction with chemotherapy to alleviate MDR mediated by ABCG2 in cancer.

4 months ago

Journal

ABCB1 (ATP Binding Cassette Subfamily B Member 1) • ABCG2 (ATP Binding Cassette Subfamily G Member 2)

mitoxantrone • topotecan

4ms

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) (clinicaltrials.gov)

P3, N=686, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting

4 months ago

Enrollment open • Metastases

gemcitabine • pemetrexed • irinotecan • vinorelbine tartrate • topotecan • sacituzumab tirumotecan (MK-2870) • Tivdak (tisotumab vedotin-tftv)

4ms

N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma (clinicaltrials.gov)

P2, N=45, Recruiting, Memorial Sloan Kettering Cancer Center

4 months ago

New P2 trial

carboplatin • temozolomide • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • irinotecan • vincristine • topotecan • Danyelza (naxitamab-gqgk) • Leukine (sargramostim)

4ms

NCI-2022-03215: Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer (clinicaltrials.gov)

P1, N=60, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended

4 months ago

Trial suspension • Combination therapy

CD4 (CD4 Molecule)

Keytruda (pembrolizumab) • Tazverik (tazemetostat) • topotecan

4ms

Phase III MIRASOL trial: Updated overall survival results of mirvetuximab soravtansine (MIRV) vs. investigator's choice chemotherapy (ICC) in patients (pts) with platinum-resistant ovarian cancer (PROC) and high folate receptor-alpha (FRÎ±) expression (ESMO 2024)

Here, we report updated nonanalytical results based on a median follow-up of 16.7 months. 453 PROC pts with high FRÎ± expression (VENTANA FOLR1 [FOLR1-2.1] RxDx Assay) with 1-3 prior therapies were randomized 1:1 to MIRV 6 mg/kg, adjusted ideal body weight, Day 1 of a 21-day cycle or ICC: paclitaxel (PAC), pegylated liposomal doxorubicin (PLD), or topotecan (Topo). With a median follow-up of 16.7 months, MIRV demonstrated improved efficacy vs ICC in pts with PROC. The efficacy data, along with the well-characterized safety profile, supports MIRV as the standard of care for pts with FRÎ± positive PROC. Clinical Trial Information: NCT04209855.

4 months ago

P3 data • Clinical

FOLR1 ( Folate receptor alpha )

FOLR1 expression

VENTANA FOLR1 RxDx Assay

paclitaxel • pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • topotecan

4ms

Consenso de expertos basado en la evidencia: perfilamiento y manejo del carcinoma epitelial de ovario de alto grado avanzado. (PubMed, Rev Colomb Obstet Ginecol)

Se sugiere utilizar bevacizumab u olaparib más bevacizumab en pacientes con CEO estadios III/IV BRCA1/2 negativo o desconocido (HRD positivo) que recibieron quimioterapia basada en platino más bevacizumab y obtuvieron RC/RP...Para pacientes con CEO de alto grado avanzado o metastásico en recaída platino-sensibles se sugiere: • Quimioterapia combinada basada en platino: carboplatino/doxorrubicina liposomal o carboplatino/paclitaxel o carboplatino/ nab-paclitaxel o carboplatino/docetaxel o carboplatino/gemcitabina, por seis ciclos. Si no se tolera la terapia combinada, dar carboplatino o cisplatino solo. • Quimioterapia combinada: carboplatino/gemcitabina o carboplatino/paclitaxel o carboplatino/doxorubicina liposomal, más bevacizumab, seguida de bevacizumab como mantenimiento (hasta progresión o toxicidad)...El paclitaxel semanal o la doxorrubicina liposomal pegilada o el topotecan pueden ser administrados con o sin bevacizumab. • Existen otros agentes que se consideran potencialmente act ivos (capecitabina, ciclofosfamida, ifosfamida, irinotecán, oxaliplatino, pemetrexed, vinorelbina, ciclofosfamida), que se podrían recomendar para líneas posteriores. • Las pacientes con receptores hormonales positivos que no toleran o no tienen respuesta a los regímenes citotóxicos pueden recibir terapia hormonal con tamoxifeno u otros agentes, incluidos los inhibidores de la aromatasa (anastrozol y letrozol) o acetato de leuprolide o acetato de megestrol...El niraparib podría ser útil en pacientes BRCA 1/2 +/-/desconocido, al igual que el rucaparib, sin embargo, este último no tiene aún aprobación del ente regulador en Colombia. Conclusiones: se espera que las recomendaciones emitidas en este consenso contribuyan a mejorar la atención clínica, el impacto oncológico y la calidad de vida de estas mujeres.

4 months ago

Clinical guideline • Journal

BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset) • PARP1 (Poly(ADP-Ribose) Polymerase 1)

Avastin (bevacizumab) • Lynparza (olaparib) • cisplatin • carboplatin • gemcitabine • tamoxifen • Zejula (niraparib) • Rubraca (rucaparib) • albumin-bound paclitaxel • pemetrexed • topotecan • megestrol • leuprolide acetate for depot suspension

4ms

Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma (clinicaltrials.gov)

P1, N=150, Completed, Children's Oncology Group | Active, not recruiting --> Completed

4 months ago

Trial completion • Trial completion date

MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)

cisplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • melphalan • busulfan • Neupogen (filgrastim)